All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Visual abstract | A phase III study of Zanubrutinib vs Bendamustine–Rituximab in CLL and SLL
By Ella Dixon
Bookmark this article
The Lymphoma Hub is happy to present a visual abstract representing key data from the phase III SEQUOIA trial (NCT03336333), evaluating the efficacy and safety of zanubrutinib as a frontline therapy in chronic lymphocytic leukemia and small lymphocytic leukemia, compared with bendamustine-rituximab. Zanubrutinib, a covalent Bruton’s tyrosine kinase inhibitor, has previously shown efficacy in phase III studies of relapsed/refractory chronic lymphocytic leukemia. The Lymphoma Hub has previously reported on the safety and efficacy of zanubrutinib in marginal zone lymphoma.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox